Federal lawsuit claims California's labor code discriminates against Vietnamese nail techs, salon owners
A federal civil lawsuit against California alleges that the state's Labor Code discriminates against Vietnamese-American manicurists and salon owners, following the passage of a 2020 law that changed how employees and independent contractors are classified.
The suit, filed in U.S. District Court in Santa Ana on Saturday, argues that only nail technicians are excluded from being classified as independent contractors due to a California law enacted in 2020.
Nail technicians, many of whom are Vietnamese-American, were also considered independent contractors before the law's passage. According to the suit, 'in California, approximately 82% of all nail manicurists/ pedicurists ('nail technicians') are Vietnamese American, and 85% of these are women.'
'The penalties for misclassifying a worker as an independent contractor are severe, and when the defendants, as heads of their enforcement agencies, enforce the new rule prohibiting nail technicians from being independent contractors, the damage to the plaintiffs will be severe and irreparable. In this regard, the salon plaintiffs will be forced out of business and will be forced to close their doors. In addition, the salon plaintiffs will be subject to significant assessments and financial penalties that will be impossible to pay,' the suit added.
California Assemblyman Tri Ta (R-Westminster) stated that he has introduced legislation, Assembly Bill 504, to restore equal rights to manicurists.
The labor law switch occurred in 2020, when AB 5, a law that altered the classification of workers as employees or independent contractors, took effect.
Before its passage, in 2018, the California Supreme Court changed the requirements companies must use to label their workers as independent contractors.
At the time, companies that opposed the bill waged a campaign to prevent its passage.
The businesses that filed the suit include multiple locations of Happy Nails & Spa, Holly and Hudson, and Blu Nail Bar.
'Since January, Vietnamese American manicurists have faced blatant discrimination under California's labor laws, stripped of the same rights and freedoms afforded to others in their industry,' Scott Wellman, attorney for the plaintiffs, said in a statement. 'If the State of California refuses to fix this injustice, we are prepared to hold them accountable in federal court.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Analog Devices' (NASDAQ:ADI) 16% CAGR outpaced the company's earnings growth over the same five-year period
Passive investing in index funds can generate returns that roughly match the overall market. But the truth is, you can make significant gains if you buy good quality businesses at the right price. For example, the Analog Devices, Inc. (NASDAQ:ADI) share price is 95% higher than it was five years ago, which is more than the market average. Zooming in, the stock is up just 3.8% in the last year. On the back of a solid 7-day performance, let's check what role the company's fundamentals have played in driving long term shareholder returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). During five years of share price growth, Analog Devices achieved compound earnings per share (EPS) growth of 4.2% per year. This EPS growth is slower than the share price growth of 14% per year, over the same period. So it's fair to assume the market has a higher opinion of the business than it did five years ago. And that's hardly shocking given the track record of growth. This optimism is visible in its fairly high P/E ratio of 64.21. You can see how EPS has changed over time in the image below (click on the chart to see the exact values). Dive deeper into Analog Devices' key metrics by checking this interactive graph of Analog Devices's earnings, revenue and cash flow. It is important to consider the total shareholder return, as well as the share price return, for any given stock. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of Analog Devices, it has a TSR of 114% for the last 5 years. That exceeds its share price return that we previously mentioned. The dividends paid by the company have thusly boosted the total shareholder return. Analog Devices shareholders gained a total return of 5.6% during the year. Unfortunately this falls short of the market return. On the bright side, the longer term returns (running at about 16% a year, over half a decade) look better. It's quite possible the business continues to execute with prowess, even as the share price gains are slowing. It's always interesting to track share price performance over the longer term. But to understand Analog Devices better, we need to consider many other factors. Case in point: We've spotted 1 warning sign for Analog Devices you should be aware of. But note: Analog Devices may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Truist Reiterates Eli Lilly (LLY) Buy Rating on Orforglipron Diabetes Drug Data
Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities reiterated its 'Buy' rating on Eli Lilly stock. The firm also maintained the price target of $1,038.00. Truist's move followed Eli Lilly's presentation at the American Diabetes Association (ADA) 85th Annual Meeting. Pixabay/Public Domain The rating pertains to Eli Lilly's oral diabetes drug, orforglipron (OFG), evaluated in the Phase 3 ACHIEVE-1 study for Type 2 diabetes treatment. The ACHIEVE-1 study results were presented at the ADA conference, showcasing orforglipron's efficacy and safety profile. The trial demonstrated statistically significant reductions in A1C (a long-term blood sugar metric) and body weight compared to placebo, with efficacy increasing at higher doses. Truist's analysis was informed by attending the orforglipron presentation, gathering feedback from KOLs at the ADA conference, and participating in Eli Lilly's investor event, where management provided clarity to alleviate safety concerns. The firm noted that longer-term data are required to further strengthen orforglipron's safety profile, particularly for chronic use in diabetes and potential obesity indications. Eli Lilly and Company (NYSE:LLY) is an American global biopharmaceutical company. The company discovers, develops, and markets prescription medicines for diabetes, obesity, cancer, immunological disorders, and neurological diseases. Its key products include Mounjaro, Zepbound, Trulicity, Verzenio, Taltz, and Jardiance. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
Yahoo
an hour ago
- Yahoo
Wells Fargo Raises Progressive (PGR) PT to $333 with Overweight Rating
The Progressive Corporation (NYSE:PGR) is one of the 12 stocks that will make you rich in 10 years. On June 20, Wells Fargo raised its price target for Progressive Corporation from $328.00 to $333.00 while maintaining an 'Overweight' rating, signaling continued confidence in the stock's upside potential. A business executive reviewing insurance policy documents with a customer. The firm acknowledged that Progressive's shares declined following a slowdown in auto policies in force (PIF) growth. However, it viewed the market reaction as excessive, highlighting that the company added a robust 246,000 policies during the month—substantially outperforming the 51,000 vehicle additions reported by Allstate. The Progressive Corporation (NYSE:PGR) is an American insurance company. It provides personal and commercial auto insurance, home and renters insurance, and specialty lines like motorcycle, RV, and boat coverage. It also offers commercial property, general liability, and workers' compensation insurance for small businesses. While we acknowledge the potential of PGR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
